We solve drug resistance

 

We are Viosera

 

The rise of multidrug resistant superbacteria and cancer has rendered many treatment options useless. We predict and block resistance evolution. 

 

 
 
Nicholas Goldner PhD, CEO goldner@viosera.com

Nicholas Goldner PhD, CEO goldner@viosera.com

Christopher Bulow PhD, COO bulow@viosera.com

Christopher Bulow PhD, COO bulow@viosera.com

Aki Kau PhD, CSO kau@viosera.com

Aki Kau PhD, CSO kau@viosera.com

 
 
Steve Trampe, CFO strampe@owendevelopment.com

Steve Trampe, CFO strampe@owendevelopment.com

Gautam Dantas PhD, Chairman Scientific Advisory Board dantas@viosera.com

Gautam Dantas PhD, Chairman Scientific Advisory Board dantas@viosera.com

 
shutterstock_1232762698 (1).jpg

MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) kills thousands of patients every year.

1 in 8 septic MRSA patients loses their life to this evolving threat.

We are developing a therapy that could save these lives.

News & Updates

Support

ycombinator-logo.png
mercyresearchlogo.png